BillionToOne Goes Public — The Startup That Made Genetic Testing Universal

BillionToOne addressed a critical gap in prenatal genetic testing by developing a non-invasive alternative to amniocentesis. Before their solution, most genetic abnormalities could only be detected through invasive procedures that were limited to high-risk pregnancies. The founders, PhD students Oguzhan Atay and David Tsao, believed they could create a universal prenatal test by sequencing fetal DNA fragments naturally present in the mother's blood.

Their approach combined biotech expertise with machine learning to analyze noisy sequencing data from free-floating DNA fragments. Despite biotech's reputation for being expensive, slow, and unpredictable, BillionToOne defied these stereotypes by moving from concept to FDA-approved commercial test in under two years on minimal seed funding. They demonstrated exceptional execution by consistently exceeding revenue targets and successfully pivoting to create COVID-19 diagnostic tests during the pandemic without missing core business goals.

The results were remarkable: today 1 in 11 babies born in the US are tested with BillionToOne's genetic test, and the company has gone public as Y Combinator's fourth biotech IPO. They've expanded into cancer detection through liquid biopsy technology, proving their platform's versatility across multiple markets.

Key takeaways for product managers include the power of combining deep technical expertise with rapid execution, the importance of maintaining focus during opportunistic pivots, and how consistent delivery against targets builds investor and market confidence even in traditionally unpredictable industries.